Clovis Oncology (NASDAQ: CLVS) calls active as shares spike
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/23/2024
- Wall St stocks end higher with major corporate earnings in view
- SAP Q1 results fall short of Wall Street estimates as transformation kicks off
- Cadence (CDNS) tumbles despite Q1 beat on top and bottom lines
- Tesla expands price cuts to China, Germany after reducing FSD cost; shares down
- Gold prices slide as M.East fears ease, rate jitters persist
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Kroger (KR), Albertsons and C&S Wholesale Grocers Announce an Updated and Expanded Divestiture Plan
- Costar Group (CSGP) to Acquire Matterport (MTTR) for $5.50/sh Cash and Stock
- Apple (AAPL) PT Lowered to $210 at Morgan Stanley, 'We'd buy post-earnings weakness'
- Jaguar Health (JAGX) Files $75M Mixed Shelf
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
- Midday movers: Tesla, Li Auto and CNH Industrial fall; Salesforce rises
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
Clovis Oncology (CLVS) Gains Again Amid Continued Takeover Chatter
September 22, 2016 10:42 AM EDTRumored takeover target Clovis Oncology (NASDAQ: CLVS) is gaining again. Shares are up 5.5%. Shares are up 189% over the last 3 months, up 109% over the last month and up 23% over the last 5 days.
... MoreClovis Oncology (CLVS) PT Raised to $45 at Stifel Amid De-Risking Events
September 21, 2016 7:30 AM EDTStifel analyst Thomas Shrader reiterated a Buy rating and raised his price target on Clovis Oncology (NASDAQ: CLVS) to $45.00 (from $30.00), saying recent events de-risk the stock.
Shrader commented, "A series of events in the last few weeks have seemed to de-risk the Clovis story including the acceptance of the rucaparib NDA, the lack of an ODAC panel and a final update for olaparib that suggests that PARP inhibitors may never show an OS benefit in the ovarian cancer (OC) maintenance setting (not... More
Clovis Oncology (CLVS) Adds to Intra-Day Gains on Rampant M&A Chatter
September 20, 2016 4:56 PM EDTClovis Oncology (NASDAQ: CLVS) adds to intra-day rumor-fueled gains after-hours. Shares are up 6% after-hours after gaining 12.7% intra-day on increased takeover chatter.
... More
